Clinical Trial Update: Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating different dose regimens of Aes-103 over 28 days in subjects with stable sickle cell disease; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Aes-103

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Sickle Cell Disease | Phase 2 | Status: TERMINATED | Results posted: 2017-03-24